Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: Results from a single-arm, open-label study

Current Medical Research and Opinion

Volumn 28, Issue 8, 2012, Pages 1395-1404

  Schmauss, Max ^a   Jukić, Vlado ^b   Siracusano, Alberto ^c   Bidzan, Leszek ^d   Badescu, George M ^e   MacIulis, Valentinas ^f   Lahaye, Marjolein ^g   Hoeben, Dagmar ^h   Tessier, Christophe ⁱ   Schreiner, Andreas ^j  

^a Bezirkskrankenhaus Augsburg   (Germany)

^b Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e Neurology and Psychiatry Clinical Hospital   (Romania)

^f Vilnius Republican Psychiatric Hospital   (Lithuania)

^g Janssen Cilag BV Netherlands   (Netherlands)

^h Janssen Pharmaceutica NV   (Belgium)

ⁱ Medical Affairs EMEA   (France)

^j JANSSEN CILAG GMBH   (Germany)

more..

Author keywords

Extended release; Flexible dosing; Paliperidone; Schizophrenia

Indexed keywords

BENZATROPINE MESILATE; BENZODIAZEPINE; BIPERIDEN; CHLORPROTHIXENE; CLOTIAPINE; CYAMEMAZINE; LEVOMEPROMAZINE; LOXAPINE; OLANZAPINE; PALIPERIDONE; PARACETAMOL; PERAZINE; PERPHENAZINE; PIPAMPERONE; PROMAZINE; TRIHEXYPHENIDYL; ZIPRASIDONE; ZOLPIDEM; ZOPICLONE;

ADULT; AGED; AGITATION; ANXIETY; ARTICLE; BREAST DISEASE; BREAST SWELLING; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; HEBEPHRENIA; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; RESIDUAL SCHIZOPHRENIA; RESTLESSNESS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; UNDIFFERENTIATED SCHIZOPHRENIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; ISOXAZOLES; MALE; MIDDLE AGED; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84864535144     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.708327     Document Type: Article

References (18)

1. Wessels T, Grü nler D, Bunk C, et al. Changes in the treatment of acute psychosis in a German public hospital from 1998 to 2004. Psychiatr Q 2007;78:91-9
2. Meulien D, Huizar K, Brecher M. Safety and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: pooled data from randomised, double-blind, placebo-controlled studies. Hum Psychopharmacol 2010;25:103-15
3. Turkoz I, Bossie CA, Lindenmayer JP, et al. Paliperidone ER and oral risperidone in patients with schizophrenia: A comparative database analysis. BMC Psychiatry 2011;11:21
4. Peuskens J. The management of schizophrenia: focus on extended-release quetiapine fumarate. Neuropsychiatr Dis Treat 2011;7:549-64
5. Birnbaum M, Sharif Z. Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER. Patient Prefer Adherence 2008;2:233-40
6. Marchese G, Pittau B, Casu G, et al. A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. Eur Psychiatry 2010;25:92-100
7. Datto C, Berggren L, Patel JB, et al. Self-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: A randomized, double-blind, crossover study in healthy adult subjects. Clin Ther 2009;31:492-502
8. Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-29
9. Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009;35:383-402
10. Fazel S, Langström N, Hjern A, et al. Schizophrenia, substance abuse, and violent crime. JAMA 2009; 301:2016-23
11. Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-70
12. Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
13. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
14. Canuso CM, Dirks B, Carothers J, et al. Randomized, double-blind, placebocontrolled study or paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009;166:691-701
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press Inc., 1994
16. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(Suppl 12):20-51
17. Morosini PL, Magliano L, Brambilia L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9
18. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-46